Key facts
- It has raised $18.1M; the latest was Accelerator/Incubator in Jan 2025.
- Notable investors include Johnson & Johnson Innovation - JLABS, AlbionVC, PharmStars, Playfair Capital, Healthtech Hub — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for uMed (Pharmaceuticals and Biotechnology)
- ·The full record, as it builds
Funding rounds
No funding rounds for uMed (Pharmaceuticals and Biotechnology) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About uMed (Pharmaceuticals and Biotechnology)
Developer of a medical research technology platform designed to provide access to healthcare research and delivery. The company's platform automates the clinical study process, creating patient registries that meet regulatory compliance and combine electronic health data with data captured from each patient that can include genomic and biomarker samples, enabling healthcare providers to participate in multiple research programs simultaneously, without increasing overhead or burdens on clinical teams.
- Sector
- Healthcare
- HQ
- London, United Kingdom
- Founded
- 2017
- Employees
- 39
- Website
- umed.io/
- Ownership
- Privately Held (backing)
uMed (Pharmaceuticals and Biotechnology) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in uMed (Pharmaceuticals and Biotechnology) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on uMed (Pharmaceuticals and Biotechnology) in its N-PORT filings yet. We sweep new filings monthly.